Beta Thalassemia Therapies
Beta Thalassemia Market

Beta Thalassemia 

Beta Thalassemia (β-thalassemia) is a blood disorder characterized by reduced synthesis of the hemoglobin subunit beta (hemoglobin beta chain) that results in microcytic hypochromic anemia, an abnormal peripheral blood smear with nucleated red blood cells, and reduced amounts of hemoglobin A (HbA) on hemoglobin analysis.

Beta Thalassemia Epidemiology Segmentation in the 6MM 

  • Total Prevalent Cases of Beta Thalassemia Minor
  • Diagnosed Prevalence of Beta Thalassemia
  • Diagnosed Beta Thalassemia Patients by Disease Type

Beta Thalassemia Epidemiological Insights Observed in the 6MM (2020)

  • The total prevalent Beta Thalassemia-associated minor cases was found to be approximately 12.5k in the year 2020.

Beta Thalassemia Market Insight

The market size of Beta Thalassemia in the 6MM was found to be almost USD 364 million in 2020.  

Beta Thalassemia Emerging Therapies

The emerging drugs in the Beta Thalassemia market are

  • Zynteglo (LentiGlobin BB305)
  • Mitapivat (AG-348)
  • IMR-687
  • CTX001
  • Vamifeport (VIT2763)
  • Sapablursen
  • Etavopivat
  • DST-0509
  • SLN-124, and others

Beta Thalassemia Key Players 

The key players working in the Beta Thalassemia market are

  • Bluebird Bio
  • Agios Pharmaceuticals
  • Imara Inc.
  • CRISPR Therapeutics
  • Vertex Pharmaceuticals
  • Vifor Pharma
  • Ionis Pharmaceuticals
  • Forma Therapeutics
  • DisperSol Technologies
  • SILENCE Therapeutics